analyst-report:-viatris-inc

Analyst Report: Viatris Inc

All Analyst Report Argus • May 27, 2026 Viatris Inc.: Raising target price to $18 Summary Viatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer’s Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has approximately 30,000

Continue Reading